The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating ...

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

Revance Therapeutics, Inc. faces financial struggles and competition, leading to a proposed takeover by Crown Labs, initially valued at $6.66 per share, later reduced to $3.10. Teoxane ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Dyne Therapeutics Inc.-5.60% $1.56B ...

With the huge research investment worldwide, the peptide-based therapeutics market is expected to grow manifolds in the future. (2) There are several peptide-based drugs available in the market ...